UPDATE: Morgan Stanley Reiterates On Celgene As EU Patents Risk May Be Underappreciated
July 16, 2014 at 10:50 AM EDT
In a report published Wednesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Celgene (NASDAQ: CELG), ...